{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T07:51:18Z","timestamp":1794210678560,"version":"4.8.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000008","name":"Health Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000008","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000014","name":"Canadian Blood Services","doi-asserted-by":"publisher","award":["CBS221511"],"award-info":[{"award-number":["CBS221511"]}],"id":[{"id":"10.13039\/501100000014","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","trasci.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.transci.2019.102710","type":"journal-article","created":{"date-parts":[[2019,12,31]],"date-time":"2019-12-31T09:06:54Z","timestamp":1577783214000},"page":"102710","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["The use of IVIg in fetal and neonatal alloimmune thrombocytopenia\u2014 Principles and mechanisms"],"prefix":"10.1016","volume":"59","author":[{"given":"Hanna","family":"Wabnitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramsha","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan H.","family":"Lazarus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.transci.2019.102710_bib0005","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1038\/s41372-019-0360-7","article-title":"Postnatal intervention for the treatment of FNAIT: a systematic review","volume":"39","author":"Baker","year":"2019","journal-title":"J Perinatol"},{"key":"10.1016\/j.transci.2019.102710_bib0010","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.bpobgyn.2019.01.017","article-title":"Foetal and neonatal alloimmune thrombocytopenia","volume":"58","author":"Winkelhorst","year":"2019","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"10.1016\/j.transci.2019.102710_bib0015","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.tmrv.2008.05.003","article-title":"Diagnosis and management of neonatal alloimmune thrombocytopenia","volume":"22","author":"Arnold","year":"2008","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.transci.2019.102710_bib0020","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1111\/trf.12671","article-title":"How do we treat fetal and neonatal alloimmune thrombocytopenia?","volume":"54","author":"Bertrand","year":"2014","journal-title":"Transfusion"},{"key":"10.1016\/j.transci.2019.102710_bib0025","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/bjh.15813","article-title":"Fetal and neonatal alloimmune thrombocytopenia: recommendations for evidence-based practice, an international approach","volume":"185","author":"Lieberman","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.transci.2019.102710_bib0030","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000488280","article-title":"Perinatal outcome and long-term neurodevelopment after intracranial haemorrhage due to fetal and neonatal alloimmune thrombocytopenia","volume":"45","author":"Winkelhorst","year":"2019","journal-title":"Fetal Diagn Ther"},{"key":"10.1016\/j.transci.2019.102710_bib0035","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/OGX.0b013e31816412d3","article-title":"Fetal\/neonatal allo-immune thrombocytopenia (FNAIT): past, present, and future","volume":"63","author":"Serrarens-Janssen","year":"2008","journal-title":"Obstet Gynecol Surv"},{"key":"10.1016\/j.transci.2019.102710_bib0040","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1080\/17474086.2017.1346471","article-title":"Fetal and neonatal alloimmune thrombocytopenia: evidence based antenatal and postnatal management strategies","volume":"10","author":"Winkelhorst","year":"2017","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.transci.2019.102710_bib0045","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1182\/blood-2016-10-739656","article-title":"Antenatal management in fetal and neonatal alloimmune thrombocytopenia: a systematic review","volume":"129","author":"Winkelhorst","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.transci.2019.102710_bib0050","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1046\/j.1423-0410.2003.00302.x","article-title":"Will it ever be possible to balance the risk of intracranial haemorrhage in fetal or neonatal alloimmune thrombocytopenia against the risk of treatment strategies to prevent it?","volume":"84","author":"Radder","year":"2003","journal-title":"Vox Sang"},{"key":"10.1016\/j.transci.2019.102710_bib0055","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/pd.2779","article-title":"Fetal and neonatal alloimmune thrombocytopenia: prenatal interventions","volume":"31","author":"Kamphuis","year":"2011","journal-title":"Prenat Diagn"},{"key":"10.1016\/j.transci.2019.102710_bib0060","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1471-0528.2007.01244.x","article-title":"Noninvasive antenatal management of fetal and neonatal alloimmune thrombocytopenia: safe and effective","volume":"114","author":"van den Akker","year":"2007","journal-title":"BJOG"},{"key":"10.1016\/j.transci.2019.102710_bib0065","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1056\/NEJM198811243192103","article-title":"Antenatal treatment of neonatal alloimmune thrombocytopenia","volume":"319","author":"Bussel","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2019.102710_bib0070","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1159\/000380907","article-title":"Low-dose versus standard-dose intravenous immunoglobulin to prevent fetal intracranial hemorrhage in fetal and neonatal alloimmune thrombocytopenia: a randomized trial","volume":"38","author":"Paridaans","year":"2015","journal-title":"Fetal Diagn Ther"},{"key":"10.1016\/j.transci.2019.102710_bib0075","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1080\/14767058.2016.1253064","article-title":"Contemporary management of neonatal alloimmune thrombocytopenia: good outcomes in the intravenous immunoglobulin era: results from the Australian neonatal alloimmune thrombocytopenia registry","volume":"30","author":"Crighton","year":"2017","journal-title":"J Matern Fetal Neonatal Med"},{"key":"10.1016\/j.transci.2019.102710_bib0080","doi-asserted-by":"crossref","first-page":"3761","DOI":"10.1182\/blood-2005-06-2235","article-title":"Antigen-positive platelet transfusion in neonatal alloimmune thrombocytopenia (NAIT)","volume":"107","author":"Kiefel","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.transci.2019.102710_bib0085","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s00431-006-0389-4","article-title":"Postnatal management of fetal and neonatal alloimmune thrombocytopenia: the role of matched platelet transfusion and IVIG","volume":"166","author":"te Pas","year":"2007","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.transci.2019.102710_bib0090","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/intimm\/dxx039","article-title":"IVIG-mediated effector functions in autoimmune and inflammatory diseases","volume":"29","author":"Galeotti","year":"2017","journal-title":"Int Immunol"},{"key":"10.1016\/j.transci.2019.102710_bib0095","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1093\/rheumatology\/41.4.367","article-title":"The therapeutic uses of intravenous immunoglobulins in autoimmune rheumatic diseases","volume":"41","author":"Pyne","year":"2002","journal-title":"Rheumatology"},{"key":"10.1016\/j.transci.2019.102710_bib0100","first-page":"81","article-title":"High-dose intravenous gammaglobulin therapy of refractory, in particular idiopathic thrombocytopenia in childhood","volume":"36","author":"Imbach","year":"1981","journal-title":"Helv Paediatr Acta"},{"key":"10.1016\/j.transci.2019.102710_bib0105","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.3928\/19382359-20161213-03","article-title":"Intravenous immunoglobulin in the treatment of primary immunodeficiency diseases","volume":"46","author":"De Ranieri","year":"2017","journal-title":"Pediatr Ann"},{"key":"10.1016\/j.transci.2019.102710_bib0110","series-title":"Guideline on core SmPC for human normal immunoglobulin for intravenous administration (IVIg)","author":"Committee for Medicinal Products for Human Use (CHMP)","year":"2018"},{"key":"10.1016\/j.transci.2019.102710_bib0115","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0887-7963(03)00038-5","article-title":"Risks associated with the use of intravenous immunoglobulin","volume":"17","author":"Pierce","year":"2003","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.transci.2019.102710_bib0120","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.transci.2016.12.017","article-title":"Mechanisms of action of intravenous immunoglobulin","volume":"56","author":"Chaigne","year":"2017","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.transci.2019.102710_bib0125","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.autrev.2016.03.018","article-title":"IVIG in autoimmune disease \u2014 potential next generation biologics","volume":"15","author":"Zuercher","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.transci.2019.102710_bib0130","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/nri3401","article-title":"Intravenous immunoglobulin therapy: how does IgG modulate the immune system?","volume":"13","author":"Schwab","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.transci.2019.102710_bib0135","first-page":"1783","article-title":"Effects of antepartum therapy for fetal alloimmune thrombocytopenia on maternal lifestyle","volume":"29","author":"Rossi","year":"2016","journal-title":"J Matern Fetal Neonatal Med"},{"key":"10.1016\/j.transci.2019.102710_bib0140","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.autrev.2006.08.011","article-title":"Safety of intravenous immunoglobulin (IVIG) therapy","volume":"6","author":"Katz","year":"2007","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.transci.2019.102710_bib0145","series-title":"Package insert GAMMAPLEX\u00ae","author":"Limited","year":"2015"},{"key":"10.1016\/j.transci.2019.102710_bib0150","series-title":"Antibody therapy: substitution \u2013 immunomodulation \u2013 monoclonal immunotherapy","first-page":"73","article-title":"Mechanisms of action and immunomodulation by IVIg","author":"Lazarus","year":"2018"},{"key":"10.1016\/j.transci.2019.102710_bib0155","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/pbc.20980","article-title":"Mechanisms of action of intravenous immunoglobulin in the treatment of immune thrombocytopenia","volume":"47","author":"Crow","year":"2006","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.transci.2019.102710_bib0160","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.autrev.2012.02.006","article-title":"Intravenous immunoglobulin: exploiting the potential of natural antibodies","volume":"11","author":"Kaveri","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.transci.2019.102710_bib0165","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.intimp.2005.11.013","article-title":"Intravenous immunoglobulin in autoimmune disorders: an insight into the immunoregulatory mechanisms","volume":"6","author":"Bayary","year":"2006","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.transci.2019.102710_bib0170","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1046\/j.1365-2141.2001.03136.x","article-title":"IVIg inhibits reticuloendothelial system function and ameliorates murine passive-immune thrombocytopenia independent of anti-idiotype reactivity","volume":"115","author":"Crow","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.transci.2019.102710_bib0175","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1586\/eci.10.9","article-title":"Mechanisms of action of intravenous immunoglobulins","volume":"6","author":"Baerenwaldt","year":"2010","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.transci.2019.102710_bib0180","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1056\/NEJM198205273062102","article-title":"Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin","volume":"306","author":"Fehr","year":"1982","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2019.102710_bib0185","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0140-6736(83)90175-7","article-title":"Effect of intravenous immunoglobulin in immune thrombocytopenia: competitive inhibition of reticuloendothelial system function by sequestration of autologous red blood cells?","volume":"322","author":"Salama","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.transci.2019.102710_bib0190","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1172\/JCI200522753","article-title":"Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease?","volume":"115","author":"Siragam","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.transci.2019.102710_bib0195","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.tmrv.2007.12.001","article-title":"The mechanisms of action of intravenous immunoglobulin and polyclonal anti-d immunoglobulin in the amelioration of immune thrombocytopenic purpura: what do we really know?","volume":"22","author":"Crow","year":"2008","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.transci.2019.102710_bib0200","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1182\/blood-2010-05-280115","article-title":"Amelioration of murine immune thrombocytopenia by CD44 antibodies: a potential therapy for ITP?","volume":"117","author":"Crow","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.transci.2019.102710_bib0205","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1182\/blood.V98.4.1095","article-title":"Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia","volume":"98","author":"Teeling","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.transci.2019.102710_bib0210","doi-asserted-by":"crossref","first-page":"674","DOI":"10.3389\/fimmu.2014.00674","article-title":"Immunomodulation by IVIg and the role of Fc-gamma receptors: classic mechanisms of action after all?","volume":"5","author":"Nagelkerke","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.transci.2019.102710_bib0215","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2003-01-0023","article-title":"IVIg-mediated amelioration of murine ITP via Fc\u03b3RIIB is independent of SHIP1, SHP-1, and Btk activity","volume":"102","author":"Crow","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.transci.2019.102710_bib0220","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1126\/science.291.5503.484","article-title":"Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor","volume":"291","author":"Samuelsson","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.transci.2019.102710_bib0225","doi-asserted-by":"crossref","first-page":"4788","DOI":"10.1073\/pnas.0807319106","article-title":"Impaired inhibitory Fc gamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy","volume":"106","author":"Tackenberg","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.transci.2019.102710_bib0230","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/nm1416","article-title":"Intravenous immunoglobulin ameliorates ITP via activating Fc\u03b3 receptors on dendritic cells","volume":"12","author":"Siragam","year":"2006","journal-title":"Nat Med"},{"issue":"Suppl. 1","key":"10.1016\/j.transci.2019.102710_bib0235","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1538-7836.2009.03420.x","article-title":"New insight into the mechanism of action of IVIg: the role of dendritic cells","volume":"7","author":"Crow","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.transci.2019.102710_bib0240","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00811","article-title":"Understanding Fc receptor involvement in inflammatory diseases: from mechanisms to new therapeutic tools","volume":"10","author":"Ben Mkaddem","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.transci.2019.102710_bib0245","doi-asserted-by":"crossref","first-page":"6403","DOI":"10.1182\/blood-2011-08-374223","article-title":"The neonatal Fc receptor (FcRn) is not required for IVIg or anti-CD44 monoclonal antibody\u2013mediated amelioration of murine immune thrombocytopenia","volume":"118","author":"Crow","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.transci.2019.102710_bib0250","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jaci.2010.10.030","article-title":"The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders","volume":"127","author":"Ballow","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.transci.2019.102710_bib0255","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1365-2141.2004.04804.x","article-title":"Intravenous (IV) anti-D and IV immunoglobulin achieve acute platelet increases by different mechanisms: modulation of cytokine and platelet responses to IV anti-D by FcgammaRIIa and FcgammaRIIIa polymorphisms","volume":"124","author":"Cooper","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.transci.2019.102710_bib0260","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature10134","article-title":"Intravenous gammaglobulin suppresses inflammation through a novel TH2 pathway","volume":"475","author":"Anthony","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.transci.2019.102710_bib0265","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","article-title":"A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis","volume":"329","author":"Dalakas","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2019.102710_bib0270","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0165-5728(96)00133-6","article-title":"Increased in vitro uptake of the complement C3b in the serum of patients with Guillain-Barre syndrome, myasthenia gravis and dermatomyositis","volume":"71","author":"Basta","year":"1996","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.transci.2019.102710_bib0275","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1002\/(SICI)1097-4598(199911)22:11<1479::AID-MUS3>3.0.CO;2-B","article-title":"Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines","volume":"22","author":"Dalakas","year":"1999","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.transci.2019.102710_bib0280","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.4049\/jimmunol.1403014","article-title":"FcRn: the architect behind the immune and nonimmune functions of IgG and albumin","volume":"194","author":"Pyzik","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.transci.2019.102710_bib0285","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00281-009-0160-9","article-title":"Immune and non-immune functions of the (not so) neonatal Fc receptor, FcRn","volume":"31","author":"Baker","year":"2009","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.transci.2019.102710_bib0290","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/337184a0","article-title":"An Fc receptor structurally related to MHC class I antigens","volume":"337","author":"Simister","year":"1989","journal-title":"Nature"},{"key":"10.1016\/j.transci.2019.102710_bib0295","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal Fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.transci.2019.102710_bib0300","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.3389\/fimmu.2017.01294","article-title":"Factors affecting the FcRn-mediated transplacental transfer of antibodies and implications for vaccination in pregnancy","volume":"8","author":"Wilcox","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.transci.2019.102710_bib0305","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1007\/s00018-010-0318-6","article-title":"The neonatal Fc receptor as therapeutic target in IgG-mediated autoimmune diseases","volume":"67","author":"Sesarman","year":"2010","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.transci.2019.102710_bib0310","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1056\/NEJM199901213400311","article-title":"Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases","volume":"340","author":"Yu","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2019.102710_bib0315","doi-asserted-by":"crossref","first-page":"422","DOI":"10.4161\/mabs.3.5.16983","article-title":"Neonatal Fc receptor and IgG-based therapeutics","volume":"3","author":"Kuo","year":"2011","journal-title":"MAbs"},{"key":"10.1016\/j.transci.2019.102710_bib0320","doi-asserted-by":"crossref","first-page":"5084","DOI":"10.1073\/pnas.0600548103","article-title":"Familial hypercatabolic hypoproteinemia caused by deficiency of the neonatal Fc receptor, FcRn, due to a mutant beta2-microglobulin gene","volume":"103","author":"Wani","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.transci.2019.102710_bib0325","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/eji.1830260327","article-title":"Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice","volume":"26","author":"Ghetie","year":"1996","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.transci.2019.102710_bib0330","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1055\/s-0037-1613331","article-title":"Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor","volume":"88","author":"Hansen","year":"2002","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.transci.2019.102710_bib0335","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.4049\/jimmunol.170.7.3528","article-title":"The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs","volume":"170","author":"Roopenian","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.transci.2019.102710_bib0340","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1038\/2031352a0","article-title":"A theoretical model of gamma-globulin catabolism","volume":"203","author":"Brambell","year":"1964","journal-title":"Nature"},{"key":"10.1016\/j.transci.2019.102710_bib0345","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0167-5699(97)01172-9","article-title":"FcRn: the MHC class I-related receptor that is more than an IgG transporter","volume":"18","author":"Ghetie","year":"1997","journal-title":"Immunol Today"},{"key":"10.1016\/j.transci.2019.102710_bib0350","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1182\/blood.V100.6.2087","article-title":"Effects of intravenous immunoglobulin on platelet count and antiplatelet antibody disposition in a rat model of immune thrombocytopenia","volume":"100","author":"Hansen","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.transci.2019.102710_bib0355","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1006\/jaut.1993.1057","article-title":"Elimination of infectious antigens and increase of IgG catabolism as possible modes of action of IVIg","volume":"6","author":"Masson","year":"1993","journal-title":"J Autoimmun"},{"key":"10.1016\/j.transci.2019.102710_bib0360","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S0140-6736(84)92294-3","article-title":"High-dose intravenous gammaglobulin for myasthenia gravis","volume":"1","author":"Fateh-Moghadam","year":"1984","journal-title":"Lancet"},{"key":"10.1016\/j.transci.2019.102710_bib0365","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa01167","article-title":"High-dose intravenous immune globulin for stiff-person syndrome","volume":"345","author":"Dalakas","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2019.102710_bib0370","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1006\/jaut.1993.1018","article-title":"ANCA anti-idiotype antibodies and the treatment of systemic vasculitis with intravenous immunoglobulin","volume":"6","author":"Jayne","year":"1993","journal-title":"J Autoimmun"},{"key":"10.1016\/j.transci.2019.102710_bib0375","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1006\/jaut.1993.1055","article-title":"The SCID mouse as a model for autoimmunity","volume":"6","author":"Hammarstr\u00f6m","year":"1993","journal-title":"J Autoimmun"},{"key":"10.1016\/j.transci.2019.102710_bib0380","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1172\/JCI24394","article-title":"Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases","volume":"115","author":"Li","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.transci.2019.102710_bib0385","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1182\/blood-2005-06-2562","article-title":"A novel murine model of fetal and neonatal alloimmune thrombocytopenia: response to intravenous IgG therapy","volume":"107","author":"Ni","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.transci.2019.102710_bib0390","first-page":"1328","article-title":"The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease","volume":"113","author":"Akilesh","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1016\/j.transci.2019.102710_bib0395","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.intimp.2018.11.040","article-title":"Generation of two high affinity anti-mouse FcRn antibodies: inhibition of IgG recycling in wild type mice and effect in a mouse model of immune thrombocytopenia","volume":"66","author":"Smith","year":"2019","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.transci.2019.102710_bib0400","doi-asserted-by":"crossref","first-page":"3660","DOI":"10.1182\/blood-2010-05-284919","article-title":"Animal model of fetal and neonatal immune thrombocytopenia: role of neonatal Fc receptor in the pathogenesis and therapy","volume":"116","author":"Chen","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.transci.2019.102710_bib0405","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1016\/S0264-410X(03)00334-7","article-title":"Placental transport of immunoglobulin G","volume":"21","author":"Simister","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.transci.2019.102710_bib0410","doi-asserted-by":"crossref","first-page":"e1007161","DOI":"10.1371\/journal.ppat.1007161","article-title":"Noncanonical placental Fc receptors: what is their role in modulating transplacental transfer of maternal IgG?","volume":"14","author":"Martinez","year":"2018","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.transci.2019.102710_bib0415","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1084\/jem.180.6.2377","article-title":"A major histocompatibility complex class I-like Fc receptor cloned from human placenta: possible role in transfer of immunoglobulin G from mother to fetus","volume":"180","author":"Story","year":"1994","journal-title":"J Exp Med"},{"key":"10.1016\/j.transci.2019.102710_bib0420","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1002\/eji.1830260718","article-title":"An IgG-transporting Fc receptor expressed in the syncytiotrophoblast of human placenta","volume":"26","author":"Simister","year":"1996","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.transci.2019.102710_bib0425","doi-asserted-by":"crossref","first-page":"985646","DOI":"10.1155\/2012\/985646","article-title":"IgG placental transfer in healthy and pathological pregnancies","volume":"2012","author":"Palmeira","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.transci.2019.102710_bib0430","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0022-3476(86)80132-9","article-title":"Transplacental passage of intravenous immunoglobulin in the last trimester of pregnancy","volume":"109","author":"Sidiropoulos","year":"1986","journal-title":"J Pediatr"},{"key":"10.1016\/j.transci.2019.102710_bib0435","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-3148.1991.tb00035.x","article-title":"The effect of intravenous immunoglobulin on placental transfer of a platelet-specific antibody: anti-P1A1","volume":"1","author":"Morgan","year":"1991","journal-title":"Transfus Med"},{"key":"10.1016\/j.transci.2019.102710_bib0440","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1046\/j.1365-2141.1997.8762507.x","article-title":"Transfer of anti-D antibodies across the isolated perfused human placental lobule and inhibition by high-dose intravenous immunoglobulin: a possible mechanism of action","volume":"96","author":"Urbaniak","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.transci.2019.102710_bib0445","doi-asserted-by":"crossref","first-page":"4537","DOI":"10.1172\/JCI57850","article-title":"The maternal immune response to fetal platelet GPIb\u03b1 causes frequent miscarriage in mice that can be prevented by intravenous IgG and anti-FcRn therapies","volume":"121","author":"Li","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.transci.2019.102710_bib0450","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1182\/blood.V74.7.2414.2414","article-title":"Inhibition of autoantibody binding to platelet glycoprotein IIb\/IIIa by anti-idiotypic antibodies in intravenous gammaglobulin","volume":"74","author":"Berchtold","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.transci.2019.102710_bib0455","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1182\/blood.V62.2.480.480","article-title":"Intravenous gammaglobulin treatment of chronic idiopathic thrombocytopenic purpura","volume":"62","author":"Bussel","year":"1983","journal-title":"Blood"},{"key":"10.1016\/j.transci.2019.102710_bib0460","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/0091-6749(89)90193-0","article-title":"Modulation of Fc receptor clearance and antiplatelet antibodies as a consequence of intravenous immune globulin infusion in patients with immune thrombocytopenic purpura","volume":"84","author":"Bussel","year":"1989","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.transci.2019.102710_bib0465","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.siny.2015.12.004","article-title":"Fetal and neonatal alloimmune thrombocytopenia","volume":"21","author":"Zdravic","year":"2016","journal-title":"Semin Fetal Neonatal Med"},{"key":"10.1016\/j.transci.2019.102710_bib0470","series-title":"Final Report Summary - PROFNAIT (Development of a prophylactic treatment for the prevention of fetal\/neonatal alloimmune thrombocytopenia (FNAIT))","author":"European Commission Research and Innovation DG","year":"2019"},{"key":"10.1016\/j.transci.2019.102710_bib0475","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1111\/j.1537-2995.2011.03480.x","article-title":"Toward a prophylaxis against fetal and neonatal alloimmune thrombocytopenia: induction of antibody-mediated immune suppression and prevention of severe clinical complications in a murine model","volume":"52","author":"Tiller","year":"2012","journal-title":"Transfusion"},{"key":"10.1016\/j.transci.2019.102710_bib0480","doi-asserted-by":"crossref","first-page":"870","DOI":"10.3324\/haematol.12515","article-title":"A prospective study of maternal anti-HPA 1a antibody level as a potential predictor of alloimmune thrombocytopenia in the newborn","volume":"93","author":"Killie","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.transci.2019.102710_bib0485","series-title":"Emergent biosolutions to manufacture prophylix AS developmental drug for fetal-neonatal alloimmune thrombocytopenia","author":"Prophylix","year":"2019"},{"key":"10.1016\/j.transci.2019.102710_bib0490","series-title":"Prophylix AS rare disease programs to be acquired by rallybio","author":"Prophylix","year":"2019"},{"key":"10.1016\/j.transci.2019.102710_bib0495","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.121905","article-title":"A recombinant human IgG1 Fc multimer designed to mimic the active fraction of IVIG in autoimmunity","volume":"4","author":"Zhang","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.transci.2019.102710_bib0500","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jaut.2017.08.004","article-title":"Recombinant human IgG1 based Fc multimers, with limited FcR binding capacity, can effectively inhibit complement-mediated disease","volume":"84","author":"Sun","year":"2017","journal-title":"J Autoimmun"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050219302836?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050219302836?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T08:51:29Z","timestamp":1761468689000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050219302836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":100,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S1473050219302836"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2019.102710","relation":{},"ISSN":["1473-0502"],"issn-type":[{"value":"1473-0502","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The use of IVIg in fetal and neonatal alloimmune thrombocytopenia\u2014 Principles and mechanisms","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2019.102710","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102710"}}